Navigation Links
Resverlogix Appoints A. Brad Cann as Chief Financial Officer
Date:10/13/2009

TSX Exchange Symbol: RVX

CALGARY, Oct. 13 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that Mr. A. Brad Cann, CA will be joining the firm on October 26, 2009 as its Chief Financial Officer. Mr. Cann will be responsible for leading the Company's financial reporting and compliance, accounting, treasury, internal audit and legal. In addition he will share responsibilities for investing, financial and partnering transactions. Resverlogix is a biotechnology company focused on delivering novel therapeutics for diseases with significant unmet medical needs. The Company is developing an oral small molecule therapeutic to treat atherosclerosis and cardiovascular disease.

"We are very pleased to add Brad to our team of professionals. He has a number of areas of expertise that will round out the collective expertise within Resverlogix including developing strategic initiatives, securing financings for publicly traded companies and he is a Chartered Business Valuator. Brad succeeds Mr. Kelly McNeill who was Resverlogix's previous CFO and he will be nominated as a corporate director at the upcoming October 15th, 2009 Annual General Meeting," said Donald J. McCaffrey, President and CEO of Resverlogix.

Previous to joining Resverlogix Mr. Cann worked for Royal Host Real Estate Investment Trust where he held a number of positions including most recently Executive Vice President and Chief Financial Officer. Prior to joining Royal Host, Brad worked as a financial and business consultant and held senior management positions with several companies including Chief Financial Officer of a sulphur export development company. Previously, Brad held various positions with a chartered accounting firm. Brad holds a Bachelor of Commerce Degree from the University of Saskatchewan and he is a Chartered Accountant and a Chartered Business Valuator.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas(TM) PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail on page 22 of the July 31, 2009 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
2. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
3. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
4. Resverlogix Provides Quarterly Update
5. Resverlogix Board of Directors Update
6. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
7. Resverlogix Announces Closing of Debt Redemption
8. Resverlogix Eliminates Sixty Percent of Remaining Debt
9. Resverlogix Issues a Management Statement
10. Resverlogix Board of Directors Update
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):